多变量模型与AJCC分期系统:在上腺皮层癌中癌症特异性生存预测
Letizia Maria Ippolita Jannello1,2,3, Simone Morra1,4, Lukas Scheipner1,5
1Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Endocrine-related cancer
|February 16, 2024
概括
一个新的模型比目前的AJCC分期系统更准确地预测上皮癌患者的癌症特异性生存率. 这种新的工具提供了更好的预后见解,特别是在早期的疾病.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 癌症研究 癌症研究
背景情况:
- 上皮层癌 (ACC) 的生存预测对于患者管理至关重要.
- 现有的分期系统,如美国癌症联合委员会 (AJCC),需要改进以提高准确性.
研究的目的:
- 开发和验证一种基于人口的新型模型,用于预测ACC患者的癌症特异性生存率 (CSS).
- 将新型号的性能与已建立的第八版AJCC分阶段系统进行比较.
主要方法:
- 使用了监测,流行病学和最终结果 (SEER) 数据库 (2004-2020年) 与1056名ACC患者.
- 用单变量和多变量考克斯回归模型进行CSS预测.
- 使用Harrell的协同指数 (C-index) 和决策曲线分析 (DCA) 验证了模型准确性,使用2000个启动重复样本.
主要成果:
- 与AJCC (0.757) 相比,多变量模型在3年CSS预测中获得了较高的C指数 (0.795),与AJCC (0.757) 相比.
- 这种新型模型在大多数预测的CSS值中在DCA中表现出卓越的性能.
- 多变量模型提供了连续范围的CSS概率,超过了AJCC系统的离散值,特别是在AJCCI和II阶段.
结论:
- 开发的基于人口的模型比AJCC分期系统更准确地预测ACC患者的CSS.
- 新型模型提供了增强的歧视和预后价值,特别是在早期的ACC.
- 这种改进的预测工具可以帮助更精确的患者分层和治疗规划.
相关概念视频
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
Assumptions of Survival Analysis
127
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
127
Kaplan-Meier Approach
138
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
138
Parametric Survival Analysis: Weibull and Exponential Methods
430
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
430
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


